一个H2S-BMP6双加载系统与调节Yap/Taz和Jun路径,用于协同关键四肢缺血救援疗法
Jiateng Hu1,2, Zhijue Xu1,2, Donghui Liao3
1Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Advanced healthcare materials
|August 2, 2023
概括
这项研究引入了一种用于关键四肢缺血治疗的新型纳米平台. 通过调节关键分子通路,UIO-66-NH2@GYY4137@BMP6系统增强了血液流动并减少了氧化应激.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 分子生物学分子生物学
背景情况:
- 关键四肢缺血症 (CLI) 是外周动脉疾病的严重阶段,其特征是血液流动不良和高氧化应激.
- 硫化 (H2S) 疗法显示出对重血管化和抗氧化作用的前景.
- 转录组分析显示,BMP6是H2S捐赠者GYY4137在HUVECs中调高的关键基因.
研究的目的:
- 开发一个共同交付的纳米平台 (UIO-66-NH2@GYY4137@BMP6) 用于增强的CLI治疗.
- 研究纳米平台的益血管和抗氧化机制.
- 在体内评估纳米平台的治疗疗效.
主要方法:
- 一个UIO-66-NH2@GYY4137@BMP6联合交付纳米平台的制造.
- 对涉及YAP/TAZ,Jun,p53和p21信号通路的分子机制的分析.
- 在体内评估使用激光多普勒输液成像 (LDPI),损伤严重程度评估和组织学分析.
主要成果:
- 该纳米平台展示了显著的益血管和抗氧化功能.
- 关键路径被调整:YAP/TAZ和Jun被调高,而p53/p21被调低.
- 在体内研究证实了CLI模型中的优秀治疗效果.
结论:
- 在UIO-66-NH2@GYY4137@BMP6纳米平台有效地治疗关键肢体缺血.
- 针对YAP,Jun和p53通路的气蛋白协同疗法为CLI提供了一个有前途的治疗策略.
更多相关视频
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
12.4K
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.7K
相关概念视频
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215